Inovio Pharmaceuticals (NASDAQ: INO) shares fell 27.9% in July, according to data provided by S&P Global Market Intelligence, after the company reported interim data from its phase 1 coronavirus vaccine trial.
Trial results weren't negative, but some investors were disappointed about the lack of detail concerning neutralizing antibodies. Neutralizing antibodies block infection, so are viewed as an essential part of a coronavirus vaccine. In its report on June 30, Inovio said 94% of trial participants showed immune response. That was measured by data on binding and neutralizing antibodies as well as T-cell responses. But Inovio didn't provide neutralizing antibody levels or compare them to the levels found in recovered coronavirus patients.
Image source: Getty Images.
Source Fool.com